In its upcoming report, Eli Lilly (LLY) is predicted by Wall Street analysts to post quarterly earnings of $1.53 per share, reflecting an increase of 1430% compared to the same period last year. Revenues are forecasted to be $12.03 billion, representing a year-over-year increase of 26.7%.The consensus EPS estimate for the quarter has been revised 0.7% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE: LLY ) for a little while now. My first article about the company, published in June 2023, touted it asCrude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses ...

In first dedicated study of a selective IL-13 inhibitor in patients previously treated with dupilumab, the majority of patients had a history of inadequate response to dupilumabEBGLYSS also provided meaningful improvements in difficult-to-treat face and hand dermatitis  The safety profile of EBGLYSS was consistent with previous Phase 3 studies and of the patients who reported eye-related events, facial dermatitis or inflammatory arthritis as the reason for prior dupilumab discontinuation, none reported simi ...

Eli Lilly and Company (LLY) will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, respectively. Earnings estimates for 2024 have declined from $16.47 to $13.83 per share over the past 30 days. The decline in estimates could be due to costs related to the acquisition of Morphic, which was closed in August and should be recorded as a charge against earnings in the third quarter.  For 2025 ...

Fewer contenders means fewer constraints on expanding market share.On the frontier of some of biopharma's lucrative markets, one competitor's stumble can be a win for one of its rivals. And it looks like Johnson & Johnson (JNJ 0.38%) just hit a bump in the road that'll pave the way for Eli Lilly (LLY 0.33%) to be more dominant in one such market within neuroscience.Here's what happened, and why it's bullish for Lilly's stock.This growing market now has one less aspiring entrantAs expected, Johnson & Johnson ...

Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all ...

Key Points **Industry/Company Involved**: - Eli Lilly and Company (LLY.N) **Core Views and Arguments**: - **Rating**: Buy - **Revenue and EPS Outlook**: LLY's 3Q24 revenue is expected to miss consensus estimates, but the company maintains its full-year revenue guidance. Non-GAAP EPS guidance is updated to reflect incremental IPR&D charges. - **Tirzepatide (Mounjaro)**: IQVIA scripts for Tirzepatide look softer than expected, but demand remains solid. LLY's manufacturing capacity for Tirzepatide is estimated at approximately 12 million injectors per month. - **Verzenio**: Sales growth is modest, with pressure from Kisqali. CDK4/6 class share is stable. - **Jardiance**: Sales growth is in line with expectations. - **Operating Margin**: Street's OpEx looks fine and in line with LLY's FY24 Operating Margin guide. - **R&D and SG&A**: LLY continues to invest in pipeline development, with R&D and SG&A increasing significantly in 2025. **Other Important Points**: - **Hurricane Helene**: Disrupted retail pharmacies and long-term care facilities in the southeastern US, potentially impacting Tirzepatide scripts by <65bps in a worst-case scenario. - **GLP-1s**: Mounjaro and Ozempic's continuous scripts (CBRx) are growing, while Trulicity's CBRx is eroding. Switching to Zepbound seems to be gaining steam, while Wegovy trends down. - **New Starts**: Mounjaro and Ozempic scripts are running parallel, with Ozempic having slightly higher new starts. - **Humalog**: Sales growth is modest, with a slight decrease in implied net price. - **Valuation**: Price target is $1,025.00, with a 52-week range of $960.02 - $553.93. - **Risks**: Macroeconomic fluctuations, counterparty exposure, issuer creditworthiness, client segmentation, regulation, changes in tax policies, currency convertibility, and settlement issues related to local clearing houses. **References**: - [1] - [2] - [3] - [4] - [5] - [6] - [7] - [8] - [9] - [10] - [11] - [12] - [13] - [14] - [15] - [16] - [17] - [18] - [19] - [20] - [21] - [22] - [23] - [24] - [25] - [26] - [27] - [28] - [29] - [30] - [31] - [32] - [33] - [34] - [35] - [36] - [37] - [38] - [39] - [40] - [41] - [42] - [43] - [44] - [45] - [46] - [47] - [48] - [49] - [50] - [51] - [52] - [53] - [54] - [55] - [56] - [57] - [58] - [59] - [60]

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in LLY over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaim ...

Eli Lilly just secured a huge win, and it's not related to the weight loss industry.Pharmaceutical powerhouse Eli Lilly (LLY 0.09%) is having a terrific 2024. Shares have gained 58% so far this year, handily outperforming both the S&P 500 and Nasdaq Composite indexes.Much of the share price appreciation can be attributed to Lilly's success in the diabetes and obesity care markets thanks to its blockbuster glucagon-like peptide-1 (GLP-1) agonists, Mounjaro and Zepbound. Moreover, Lilly made headlines back in ...

Core Viewpoint - Eli Lilly and Company (LLY) has experienced a decline in stock value due to recent FDA decisions regarding its GLP-1 drug tirzepatide, despite the company's strong performance and growth prospects in the pharmaceutical market [1][2][3]. Group 1: Stock Performance and Market Impact - LLY's stock has declined 1.7% this week, resulting in a loss of nearly $14 billion in market value [1]. - The FDA's recent decision to review the removal of tirzepatide from its shortage list has negatively impacted LLY's shares [2][3]. - Despite this setback, LLY's stock has risen 57.3% this year, outperforming the Large Cap Pharmaceutical industry and the S&P 500 [8]. Group 2: Product Portfolio and Pipeline - Tirzepatide, marketed as Mounjaro and Zepbound, has become a key revenue driver, generating approximately $6.7 billion in sales in the first half of 2024, accounting for around 44% of total revenues [4]. - LLY has invested over $18 billion since 2020 to enhance manufacturing capabilities, which is now benefiting the supply of its drugs [4]. - The company has received approvals for several new drugs, including Kisunla for Alzheimer's disease, which is expected to generate significant sales [6][7]. Group 3: Competitive Landscape - LLY's tirzepatide faces competition from Novo Nordisk's semaglutide, which is also in high demand but remains in short supply [5]. - The company is developing tirzepatide for additional indications, which could further enhance its market position [5]. Group 4: Financial Outlook - Earnings estimates for LLY have decreased from $16.49 to $14.41 per share for 2024, attributed to acquisition-related costs, while estimates for 2025 have increased from $22.79 to $24.16 per share [9][10]. - LLY's strong revenue growth is driven by the demand for its key products, which is expected to offset declines from other drugs [11][12].